Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.2K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
1.1K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

3.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

820
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
820

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Geriatrics Connect: Countering ageism in first-year medical students with longitudinal telephonic relationships.

Gerontology & geriatrics education·2025
Same author

Practice Makes Perfect: Objective Structured Clinical Examinations Across the UME-to-GME Continuum Improve Care of Transgender Simulated Patients.

Journal of graduate medical education·2024
Same author

Development and Validation of a Machine Learning Model for Automated Assessment of Resident Clinical Reasoning Documentation.

Journal of general internal medicine·2022
Same author

History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications.

Cancer drug resistance (Alhambra, Calif.)·2022
Same author

PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues.

Cancer drug resistance (Alhambra, Calif.)·2022
Same author

Lessons in clinical reasoning ‒ pitfalls, myths and pearls: a case of recurrent pancreatitis.

Diagnosis (Berlin, Germany)·2021

Related Experiment Video

Updated: May 4, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.0K

Novel taxanes.

Franco Muggia1, David Kudlowitz

  • 1NYU Cancer Institute, New York, New York, USA.

Anti-Cancer Drugs
|December 31, 2013
PubMed
Summary
This summary is machine-generated.

New taxane formulations, including novel analogs and immunotoxins, aim to enhance cancer treatment efficacy and reduce toxicity. These advanced chemotherapy drugs are under investigation for various cancer types.

More Related Videos

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
08:41

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

22.6K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.0K

Related Experiment Videos

Last Updated: May 4, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.0K
Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
08:41

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

22.6K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.0K

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Development

Background:

  • Paclitaxel, a key chemotherapy agent, has seen numerous new formulations since the 1990s.
  • Next-generation taxanes are being developed to improve efficacy, reduce toxicity, and overcome drug resistance.
  • Innovations include new analogs and immunotoxins targeting cancer cells more specifically.

Purpose of the Study:

  • To review the development and clinical efficacy of novel taxane formulations.
  • To highlight advancements in chemotherapy aimed at improving cancer treatment outcomes.
  • To discuss the potential of next-generation taxanes and immunotoxins in oncology.

Main Methods:

  • Review of clinical studies and scientific literature on taxane derivatives.
  • Analysis of new taxane formulations, including cabazitaxel, paclitaxel poliglumex, and immunotoxins.
  • Examination of ongoing phase II and III trials for various cancer types.

Main Results:

  • Several new taxane formulations like cabazitaxel and paclitaxel poliglumex demonstrate clinical efficacy.
  • Immunotoxins such as trastuzumab emtansine show increased cytotoxicity and specificity.
  • Ongoing studies are evaluating these advanced chemotherapeutics across diverse cancers.

Conclusions:

  • Novel taxane formulations and immunotoxins represent significant advancements in cancer therapy.
  • These agents offer improved therapeutic profiles, targeting cancer cells more effectively.
  • Further research and clinical trials are crucial for optimizing their use in oncology.